DRMA — Dermata Therapeutics Cashflow Statement
0.000.00%
Annual cashflow statement for Dermata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.9 | -9.61 | -7.79 | -12.3 | -7.56 |
| Depreciation | |||||
| Non-Cash Items | 1.92 | 0.93 | 0.522 | 0.658 | 0.144 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.29 | -0.154 | 0.864 | 0.467 | -0.343 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -5.69 | -8.83 | -6.41 | -11.2 | -7.76 |
| Financing Cash Flow Items | — | — | -0 | -0.001 | -0.051 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16 | 4.28 | 7.61 | 6.89 | 12.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.3 | -4.56 | 1.2 | -4.28 | 4.36 |